Melanotan II research peptide is supplied to qualified Canadian institutions as a characterized laboratory material for in vitro melanocortin-receptor pharmacology. The compound is a cyclic heptapeptide analogue of α-melanocyte-stimulating hormone (MT-II).

In vitro, the lactam bridge confers conformational rigidity and metabolic stability relative to linear α-MSH. Melanotan II is non-selective across MC1R, MC3R, MC4R, and MC5R, which is why it is used as a reference agonist when an assay must occupy the melanocortin family rather than a single subtype. Typical designs record cAMP or reporter readouts in receptor-expressing cells and compare subtype-selective ligands. This listing describes receptor pharmacology in experimental systems only and does not assign a cosmetic or clinical use.

The material is offered as a lyophilized vial. Identity data (CAS 121062-08-6, formula C50H69N15O9, molecular weight 1024.2 g/mol, sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, PubChem CID 92432) are listed on the specification table. Store lyophilized at −20 °C, protected from light, and handle under the receiving institution's chemical-hygiene plan.

Lots are sourced from a GMP-aligned peptide manufacturing partner and released against the stated HPLC purity for that lot (≥98% by HPLC, lot-specific). Identity, chromatographic purity, and related analytical results are documented on the lot certificate of analysis (COA). Retain the COA with the inventory record.

This listing is a research-use-only peptide offered to qualified Canadian institutions for in vitro and laboratory use. Purchasing access is limited to verified Canadian research institutions; individual consumer accounts are not accepted. It is not for human or veterinary use, is not intended for diagnostic procedures, and has not been evaluated or authorized by Health Canada as a drug, diagnostic, or medical product.